Evidence map›Paper›PMID 25080600›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2014

Cyclin-dependent kinase 5 mediates adult OPC maturation and myelin repair through modulation of Akt and GsK-3β signaling.

FuCheng Luo, Kathryn Burke, Christopher Kantor, Robert H Miller, Yan Yang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.Journal of cellular and molecular medicine · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. The role of Cdk5 in neurological disorders.Frontiers in cellular neuroscience · 2022
    Review
  12. Three decades of Cdk5.Journal of biomedical science · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. R-Ras GTPases Signaling Role in Myelin Neurodegenerative Diseases.International journal of molecular sciences · 2020
    Review
  17. The Role of CDKs and CDKIs in Murine Development.International journal of molecular sciences · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

FuCheng LuoDepartments of Neurosciences and.
Kathryn BurkeDepartments of Neurosciences and.
Christopher KantorDepartments of Neurosciences and.
Robert H MillerDepartments of Neurosciences and Neurology and Center for Translational Neurosciences, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106 rhm3@case.edu yxy33@case.edu.
Yan YangNeurology and Center for Translational Neurosciences, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106 rhm3@case.edu yxy33@case.edu.
Center for Neurosciences · USCase Western Reserve University · USNeurology, Inc · US

Funding

Cdk5 regulates oligodendrocyte development, myelination and repairR01NS077942 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI MILLER, ROBERT H., YANG, YAN · 2011 to 2015
$1.7M
NINDS NIH HHS R01 NS077942NINDS NIH HHS R01NS077942
6 · The paper itself

Abstract

Failure of remyelination in diseases, such as multiple sclerosis (MS), leads to permanent axonal damage and irreversible functional loss. The mechanisms controlling remyelination are currently poorly understood. Recent studies implicate the cyclin-dependent kinase 5 (Cdk5) in regulating oligodendrocyte (OL) development and myelination in CNS. In this study, we show that Cdk5 is also an important regulator of remyelination. Pharmacological inhibition of Cdk5 inhibits repair of lysolecithin lesions. This inhibition is a consequence of Cdk5 disruption in neural cells because remyelination in slice cultures is blocked by Cdk5 inhibitors, whereas specific deletion of Cdk5 in OLs inhibits myelin repair. In CNP-Cre;Cdk5(fl/fl) conditional knock-out mouse (Cdk5 cKO), myelin repair was delayed significantly in response to focal demyelinating lesions compared with wild-type animals. The lack of myelin repair was reflected in decreased expression of MBP and proteolipid protein and a reduction in the total number of myelinated axons in the lesion. The number of CC1(+) cells in the lesion sites was significantly reduced in Cdk5 cKO compared with wild-type animals although the total number of oligodendrocyte lineage cells (Olig2(+) cells) was increased, suggesting that Cdk5 loss perturbs the transition of early OL lineage cell into mature OL and subsequent remyelination. The failure of remyelination in Cdk5 cKO animals was associated with a reduction in signaling through the Akt pathway and an enhancement of Gsk-3β signaling pathways. Together, these data suggest that Cdk5 is critical in regulating the transition of adult oligodendrocyte precursor cells to mature OLs that is essential for myelin repair in adult CNS.

Indexed as

2',3'-Cyclic Nucleotide 3'-PhosphodiesteraseAnalysis of VarianceAnimalsCerebellumCyclin-Dependent Kinase 5Demyelinating DiseasesDisease Models, AnimalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaIn Vitro TechniquesLipopolysaccharidesMiceMice, Inbred C57BLMice, TransgenicMicroscopy, Electron, TransmissionMyelin Sheath2',3'-Cyclic Nucleotide 3'-PhosphodiesteraseCnp protein, mouseCyclin-Dependent Kinase 5Glycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, mouseLipopolysaccharidesProto-Oncogene Proteins c-aktcyclin-dependent kinase 5demyelinationmyelinationoligodendrocyteremyelination

Identifiers

PMID25080600
PMCPMC4115145
OpenAlexW1979104943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.